High blood pressure is often managed through at-home self-monitoring, a routine which can be difficult to manage for patients with hectic lifestyles. Now, Japanese medtech giant Omron may have the solution.
Omron (OMRNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.